Idarucizumab for Dabigatran Reversal Approved

Idarucizumab for Dabigatran Reversal Approved
Oct 26, 2015 10:14am

On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.

0 Comments

On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.

Leave A Comment

You must be logged in to Comment - Sign In